Treatment of headache by injection of neuroinhibitory substance to sphenopalatine ganglion or otic ganglion
AssigneeNorwegian University of Science and Technology (Ntnu)
InventorsDaniel Fossum Bratbak, Ståle Nordgård
Life of this patent
Estimating the term…
Abstract
A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG.
Claims28
A method comprising injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion (“SPG”) or otic ganglion (“OG”), wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance is injected in close proximity to the SPG or OG.
(canceled)
A method comprising treating or preventing headache in a patient in nee thereof, wherein the treatment or prevention comprises injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion or otic ganglion, wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion (“SPG”) or otic ganglion (“BOG”) by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance injected in close proximity to the SPG or OG.
A method comprising treating or preventing rhinitis, rhinosinusitis, Frey syndrome or hypersecretion of tears in a patient in need thereof, wherein the treatment or prevention comprises injecting a neuroinhibitory substance in close proximity to the sphenopalatine ganglion or otic ganglion, wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically, and the neuroinhibitory substance injected in close proximity to the SPG (“SPG”) or OG (“OG”).
(canceled)
Dependencies are inferred from the claim text.